PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients
about
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsActivation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysisNotch signaling in prostate cancer: a moving targetMethodological aspects of the molecular and histological study of prostate cancer: focus on PTENMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerInsulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors.Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerTumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomasRecurrent prostate cancer genomic alterations predict response to brachytherapy treatmentMolecular pathways and targets in prostate cancerPrevention and early detection of prostate cancer.Clonal progression of prostate cancers from Gleason grade 3 to grade 4.Can we accurately report PTEN status in advanced colorectal cancer?Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancerPTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate CancerPTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factorsPaucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsMolecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization StudyIdentification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Should Gleason 6 be labeled as cancer?Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
P2860
Q26752510-1E5D22FD-905E-461A-9FEF-E56B859BC8F6Q26830671-7112498D-7350-4330-9B71-FC7DF0170BC9Q27001047-931278E9-A1CE-4118-B0B4-D3F6CAD72112Q27005677-4D5859A5-8F32-4EC4-B467-85858D28247AQ27024775-D75FF126-B931-4669-8F17-291187C5A899Q30381117-DACD4936-3137-4BFD-8B2E-01B054FA61DDQ30557008-575B226E-020B-42A1-8432-3FC9E04AB27CQ30572057-BECBA09F-AAC9-4438-8E17-9841AB892FF6Q30573750-D9926C63-8D96-4995-913E-68E675BEE2ADQ33414685-6A6A8B55-A255-4C75-9C8A-C17BECDC1AA2Q33642302-5FF18F06-CD57-4289-B857-6A7926E4ED04Q33852664-7BEEDF4D-8635-4483-89D7-DADE0CD3D93DQ34365632-3230A8EA-D473-4241-8835-67492809C900Q34371057-63F3CD46-E813-4983-A753-117CCF22DAECQ34498069-8EE6E8D3-D064-4D8D-BD85-5551A72F702AQ35101357-E3BC6F4C-FEA0-4F83-89A5-CFE1DFA40C55Q35132292-3C0097A3-545F-4A93-90D2-3357411F58F2Q35176084-5915F28F-28C2-4015-A7F0-C203049B7386Q35234584-F39226EA-A76B-4181-A592-BD68FB7BE367Q35540013-6894EA31-3481-4B92-86B5-09CA9EAACAAAQ35586422-09810307-8282-4B55-A538-91C47ECDDAAEQ35854235-EDE150F6-FDF3-4F27-A34D-773769822AABQ35873154-9E718C1B-4565-401B-A991-9690F6A66027Q36193912-7730B0B4-1439-4208-866F-F3008926A49FQ36199762-6CD562DD-2408-434B-8EED-18B46AB1FD76Q36235829-4ABF0D49-6C8E-45F8-BE51-B5EB681EC2B2Q36269232-F0AF93C2-486A-488B-ABB8-C5CCB09310DCQ36287422-806C1052-9578-481A-99DD-DF2B7B2DAA7EQ36469889-C25FB7C9-0045-4F28-8B8B-3F594A129248Q36610246-3A2E76DF-036B-4BFE-9840-495E33206FDDQ36724548-860285B0-D4B6-4610-91DC-1242C6EA790FQ36742601-C2BCE5C1-A182-4D9D-AD15-060BC41CB1DCQ36753720-2EA8ED54-A1EE-4520-B949-972974E624EEQ36887707-5DAA3B44-1DEF-4B8E-8D7D-ADAA34B0EDD5Q36901964-F1CA36E7-365F-4A9C-9583-42A69E35C6F9Q36931932-40D16542-073C-4A4C-BF59-71897514E40BQ36959119-9CAD2F4C-2F35-4212-9307-25C01F1C2407Q36965321-717100F9-8420-455E-809C-110FA5C0B049Q37029385-C1E9A912-7525-48B3-8B44-32AF92FF33F9Q37080378-2B1351B2-80E6-4BBD-987E-B08FA19FDE97
P2860
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PTEN protein loss by immunosta ...... rt of prostate cancer patients
@en
type
label
PTEN protein loss by immunosta ...... rt of prostate cancer patients
@en
prefLabel
PTEN protein loss by immunosta ...... rt of prostate cancer patients
@en
P2093
P2860
P50
P1476
PTEN protein loss by immunosta ...... rt of prostate cancer patients
@en
P2093
Angelo M De Marzo
Ben H Park
Bora Gurel
David Esopi
Elizabeth Humphreys
George J Netto
Jessica L Hicks
Siobhan Sutcliffe
Wennuan Liu
P2860
P304
P356
10.1158/1078-0432.CCR-11-1244
P407
P577
2011-08-30T00:00:00Z